SMARCA4 deficiency/partial deficiency in chest tumors
Conditions
Interventions
SMARCA4 deficient/partially deficient chest tumor patients:After the progression of the disease caused by first-line drug resistance, second-line administration of bevacizumab combined with anti-PD-1
Sponsors
Fuyang People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Enrollment age: patients aged 18-80, regardless of gender, smoking or non-smoking status. 2. Collect cases of thoracic tumors with confirmed pathological diagnosis of SMARCA4 deletion/partial deletion (patients with postoperative recurrence or stage II-IV patients who cannot undergo surgery).
Exclusion criteria
Exclusion criteria: 1.PS>2 points; 2.Exclude patients with uncontrolled diabetes, serious cardiovascular and cerebrovascular diseases or liver and kidney function damage, coagulation dysfunction and thrombosis; 3.Exclude patients with psychological or psychiatric disorders and poor compliance;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR) ;Progression-Free Survival (PFS) ;Overall Survival (OS) ;Disease Control Rate (DCR); | — |
Countries
China
Contacts
Public ContactJIANG QING
Fuyang People's Hospital
Outcome results
None listed